Company / Accounts Receivable
Fortress Biotech, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$29.8M
FY2025
5-year range
$10.2M / $29.8M
FY2021-FY2025
Trend
+191.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable returned to growth in FY2025 after 2 years of decline, reaching $30M.
Based on SEC 10-K filings.
$30M in FY2025 with a 5-year CAGR of +17.1%.
Improved from $15M to $30M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +1.8%
- 5-Year CAGR
- +17.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +17.1%, indicating consistent growth.
- In FY2025, accounts receivable increased 191.1% year-over-year.
- Lowest accounts receivable in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $29.8M | +191.1% |
| FY2024 | $10.2M | -32.8% |
| FY2023 | $15.2M | -46.0% |
| FY2022 | $28.2M | +22.0% |
| FY2021 | $23.1M | +70.7% |
| FY2020 | $13.5M | +0.0% |
| FY2019 | $13.5M | +146.3% |
| FY2018 | $5.5M | -29.1% |
| FY2017 | $7.8M | +323.9% |
| FY2016 | $1.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026